An overview of insulin glargine

被引:16
作者
Home, PD [1 ]
Ashwell, SG [1 ]
机构
[1] Newcastle Univ, Sch Med, Dept Diabet & Metab, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
关键词
basal insulin; diabetes; hypoglycaemia; insulin glargine; NPH insulin;
D O I
10.1002/dmrr.317
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Insulin glargine is an innovative, long-acting human insulin analogue, whose prolonged mean activity profile has no pronounced peak. Accordingly, it mimics more closely the natural physiological profile of basal endogenous insulin secretion than do traditional extended-acting insulins such as NPH insulin. As would be expected for a more satisfactory basal insulin, clinical trials comparing insulin glargine with NPH insulin show less nocturnal hypoglycaemia, improved pre-breakfast blood glucose levels, or both. no substantive safety concerns have emerged for insulin Furthermore, insulin glargine represents the first major advance in the glargine. Thus, insulin glargine represents the first major advance in the provision of basal insulin injection therapy for people with type 1 and type 2 diabetes for over 50 years. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:S57 / S63
页数:7
相关论文
共 33 条
[11]   Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus [J].
Füchtenbusch, M ;
Standl, E ;
Schatz, H .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2000, 108 (03) :151-163
[12]   CRYSTALLINE AND AMORPHOUS INSULIN-ZINC COMPOUNDS WITH PROLONGED ACTION [J].
HALLASMOLLER, K ;
PETERSEN, K ;
SCHLICHTKRULL, J .
SCIENCE, 1952, 116 (3015) :394-398
[13]   Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo [J].
Heinemann, L ;
Linkeschova, R ;
Rave, K ;
Hompesch, B ;
Sedlak, M ;
Heise, T .
DIABETES CARE, 2000, 23 (05) :644-649
[14]  
HOLMAN RR, 1989, DIABETIC MED, V6, pA41
[15]  
HOME PD, 2002, DIABETOLOGIA, V44
[16]  
Krayenbuhl C., 1946, REP STENO MEMORIAL H, V1, P60
[17]  
KRUSZYNSKA YT, 1988, DIABETES METAB, V14, P437
[18]   BASAL AND 24-H C-PEPTIDE AND INSULIN-SECRETION RATE IN NORMAL MAN [J].
KRUSZYNSKA, YT ;
HOME, PD ;
HANNING, I ;
ALBERTI, KGMM .
DIABETOLOGIA, 1987, 30 (01) :16-21
[19]   Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use [J].
Kurtzhals, P ;
Schäffer, L ;
Sorensen, A ;
Kristensen, C ;
Jonassen, I ;
Schmid, C ;
Trüb, T .
DIABETES, 2000, 49 (06) :999-1005
[20]   Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro [J].
Lepore, M ;
Pampanelli, S ;
Fanelli, C ;
Porcellati, F ;
Bartocci, L ;
Di Vincenzo, A ;
Cordoni, C ;
Costa, E ;
Brunetti, P ;
Bolli, GB .
DIABETES, 2000, 49 (12) :2142-2148